Jazz Pharmaceuticals (JAZZ) Shares Outstanding (Weighted Average) (2010 - 2026)

Jazz Pharmaceuticals has reported Shares Outstanding (Weighted Average) for 17 years, with the latest figure at $61.9 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 1.48% year-over-year to $61.9 million; the trailing twelve-month figure through Mar 2026 stood at $61.9 million (up 1.48% YoY), and the FY2025 full-year result was $61.0 million, down 1.39% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $61.9 million, up from $61.0 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $63.7 million in Q2 2023, with the low at $60.7 million in Q3 2025.
• Average Shares Outstanding (Weighted Average) over 5 years is $62.2 million, with a median of $62.3 million recorded in 2024.
• Year-over-year, Shares Outstanding (Weighted Average) increased 9.56% in 2022 and declined 2.85% in 2025.
• Tracing JAZZ's Shares Outstanding (Weighted Average) over 5 years: stood at $62.5 million in 2022, then increased by 1.2% to $63.3 million in 2023, then dropped by 2.3% to $61.8 million in 2024, then fell by 1.39% to $61.0 million in 2025, then advanced by 1.51% to $61.9 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $61.9 million (Q1 2026), $61.0 million (Q4 2025), and $60.7 million (Q3 2025), per Business Quant data.

Peer Comparison